FIELD: biotechnology.
SUBSTANCE: invention relates to a method for engraftment of a human hematopoietic cell, comprising administering at least one human hematopoietic cell to a genetically modified immunodeficient mouse, containing in its genome nucleic acid coding human M-CSF, nucleic acid coding human IL-3, nucleic acid coding human GM-CSF, nucleic acid coding human SIRPA, and nucleic acid coding human TPO. Also disclosed is a method for transplantation of human cancer cells to a mouse, which was engrafted with human hematopoietic cells using the above mentioned method.
EFFECT: invention is effective for producing mice as a model for studying human hematopoiesis and immune fraction in vivo.
23 cl, 17 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHOD FOR THEIR APPLICATION | 2013 |
|
RU2642319C2 |
| GENETICALLY MODIFIED ANIMALS NOT RELATED TO HUMAN RACE AND THEIR APPLICATION METHODS | 2013 |
|
RU2775425C2 |
| GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS FOR USE THEREOF | 2013 |
|
RU2673156C2 |
| NON-HUMAN GENETICALLY MODIFIED ANIMALS EXPRESSING HUMAN EPO | 2015 |
|
RU2711744C1 |
| GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO | 2015 |
|
RU2799086C2 |
| HUMANISED MOUSE M-CSF | 2012 |
|
RU2577978C2 |
| MODEL OF HLA-INCOMPATIBLE HUMANIZED NSG MOUSE WITH XENOGRAFT OBTAINED FROM A PATIENT | 2016 |
|
RU2757421C2 |
| HUMANIZED M-CSF MICE | 2020 |
|
RU2819731C2 |
| HUMANISED M-CSF MICE | 2012 |
|
RU2730643C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
